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Abstract 
Objectives 
Epidemiological data have shown that individuals with advanced fibrosis are at greatest 
risk of premature morbidity in NAFLD. Individuals included in clinical trials are often highly 
selected to remove confounding factors but selection can introduce bias and limit external 
validity. We examined the external validity of trials in non-alcoholic fatty liver disease 
(NAFLD) by examining characteristics of participants in observational studies (OS) and 
randomised controlled trials (RCT) in NAFLD. 
Design 
A systematic review was performed with structured literature searches for relevant OS and 
RCT using PubMed and Ovid Embase (1948 - 2016). Identified studies were screened for 
inclusion by the authors and data extracted. Study populations were compared using t-
tests to compare means and variances, in each case weighted by the size of individual 
studies. Dichotomous data were compared by Chi-squared test.  
Results  
In total 148 studies were included: 67 RCT and 81 OS including data from 44,860 
individuals . Fifteen RCT participants differed from individuals in OS with regard to age, 
BMI, prevalence of DM, and gender (p<0.001 in each case). The most pronounced 
differences were seen between RCT participants and patients with advanced fibrosis. Co-
morbid conditions prevalent amongst individuals with NAFLD were frequent exclusion 
criteria in RCT.   
Conclusions  
The characteristics of participants in randomised controlled trials differ to those of the 
wider population of individuals with NAFLD. These differences may reduce the utility of 
trial data to individuals with NAFLD at greatest risk of death. 
 
Key words: Non-alcoholic fatty liver disease, Non-alcoholic steatohepatitis, Systematic 
review  
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Non-alcoholic fatty liver disease (NAFLD) is a spectrum of disease, ranging from simple 
hepatic steatosis through non-alcoholic steatohepatitis (NASH), to cirrhosis (1). NAFLD is 
common: hepatic steatosis is present in up to one-third of individuals (2) and NASH is 
seen in approximately 10% (3). Whilst the association of NAFLD per se with mortality is 
debated (4), large studies have shown that it is the subset of patients with advanced 
fibrosis who have an increased risk of liver-related morbidity as well as cardiovascular and 
neoplastic disease (5, 6).  Given the high prevalence of NAFLD there is a need for effective 
therapies to prevent progression of disease and to treat established fibrosis. However, 
whilst many treatments have been trialed, few have shown categorical benefit in NASH 
(7).  
 
The external validity of a trial describes its relevance to a population outside of the trial’s 
participants (8). Systematic analyses of trials in cardiology (9) and respiratory medicine (10, 
11) have demonstrated have poor external validity, where commonly occurring medical 
conditions and age often exclude individuals from participation in trials (12). Poor external 
validity may promote ineffective treatments or, conversely, limit the acceptance of 
effective treatments (8). We used systematic review methods to assess the characteristics 
of participants included in randomised controlled trials (RCT) for treatment of NAFLD and 
the characteristics of individuals described in observational studies (OS) of NAFLD. This 
allowed comparison of the two groups and therefore an estimate of the external validity 
of RCTs performed in NAFLD to date. 
Methodology 
Literature search 
Literature searching was undertaken using three search strategies, to identify OS for 
NAFLD, OS reporting advanced fibrosis, and to identify randomised controlled trials in 
NAFLD. PubMed/MedLine and Ovid Embase were searched (1948 - 2016), using the 
search terms: ((((randomised controlled trial) AND non alcoholic steatohepatitis) OR 
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NASH) OR NAFLD) OR non-alcoholic fatty liver disease) for RCT, and  (((Prevalence[Title]) 
OR Natural history[Title])) AND ((((non-alcoholic fatty liver disease) OR NASH) OR NAFLD) 
OR non-alcoholic steatohepatitis) and (fibrosis OR histology) AND (NASH OR non-
alcoholic steatohepatitis) for OS. Results were limited to human studies and those 
published in English. The literature search was performed 1/7/2014 and updated on 
11/8/2016. To examine ‘grey literature’ for suitable studies the reference lists of included 
studies were searched for other suitable studies, and papers citing included studies were 
also reviewed. The title and abstract  of papers found by the literature search were 
reviewed and unsuitable manuscripts or duplicate results excluded. Remaining papers 
were reviewed independently by two authors (RP, IAC) and disagreements resolved by 
consensus. This report is the only published account of this protocol. 
 
Inclusion and exclusion criteria 
Papers were included if they were full papers describing RCTs of interventions (lifestyle or 
pharmacological) in adult patients with any stage of NAFLD, or full papers reporting OS of 
prevalence or natural history of NAFLD in adults. Instances where the same cohort was 
described in more than one study were identified and included only once, with the study 
containing the most data included or the most recent report if descriptions were similar.  
Studies that had been published as abstracts, and those published in languages other 
than English were excluded. OS that only included particular groups, for example, studies 
reporting the prevalence of NAFLD amongst patients undergoing bariatric surgery, were 
also excluded. 
 
Data extraction 
Papers were reviewed and data extracted into a pre-prepared spreadsheet. Mean values 
for characteristics of trial participants in RCTs and individuals in OS were noted, specifically 
age, BMI, gender (% of male participants), prevalence of Diabetes mellitus (DM). For RCTs, 
type of intervention, primary outcome, secondary outcome and exclusion criteria were 
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recorded, as well as whether the trial reported a positive or negative finding. In the 
first instance, all OS were included in analysis of NAFLD as a whole, encompassing all 
stages of disease. Subsequent analyses were undertaken for biopsy-proven NASH 
and advanced fibrosis, including only OS that used and reported biopsy findings. For 
measurement of fibrosis in studies including biopsies, the Kleiner/Brunt classification 
was often used where F3 or F4 was taken to indicate advanced fibrosis, as is usual in 
the field. In studies that did not use the Kleiner/Brunt classification, advanced fibrosis 
was considered as bridging fibrosis or cirrhosis. The quality of included studies was 
assessed using the CONSORT guidelines for RCT (13) and the STROBE guidelines for 
observational studies (14).  
 
Data synthesis and analysis 
Many papers reported mean values for each arm of a trial but not an overall mean. 
Where this occurred, overall weighted means and variances were produced for the study 
as a whole, using the formulae        
 
       
 
   and           
  
           
 
   
respectively. Once every study was represented by a single mean and variance, they were 
then split by study type (RCT or OS), and overall pooled means and variances calculated 
using the same approach.  
 
Comparisons were initially made between the study types with Kruskal-Wallis tests to 
produce an unweighted comparison of reported means or prevalences between the study 
types. As this does not take the size of studies into account, comparisons were then made 
using t-tests on the pooled means and variances. Variances were tested with F test, with 
Welch’s correction used when they differed significantly by study type. Sub-group 
analyses were performed by stratifying data by geography, and by quality of RCTs. 
 
For the dichotomous outcomes (diabetes mellitus, gender), the overall rates were 
calculated by based on the total number of individuals  with diabetes, or total number of 
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males in each type of study and calculating a percentage based on the total available 
data. This again removes the bias of larger studies dominating the data when only 
reported percentages were considered. Comparisons between study types were then 
performed using Chi-square tests. A p value of less than 0.05 was considered significant in 
all analyses. Prism v5.0 (Carlsbad, California USA) was used for statistical analysis.  
Results 
Literature search 
The search strategies resulted in a total of 1165 studies being identified. After removal of 
irrelevant studies and duplicated data, a total of 143 studies were included (figure 1). The 
quality of included studies, assessed with reference to the CONSORT and STROBE 
guidelines for RCT and OS respectively, showed most studies to be of high quality 
(supplementary figure 1). 
 
Characteristics of included studies 
In total eighty-one observational studies were included, including data on a total of 
40,014 individuals with NAFLD. Twenty-four studies were population-based studies that 
described individuals with NAFLD in a general population, and fifty-two described 
characteristics of patients with NAFLD in secondary or tertiary centres. Seventy-three 
studies described all stages of NAFLD, including 34,147 individuals (supplementary table 
1). Eighteen studies including 2,780 individuals described patients with biopsy-proven 
NASH (supplementary table 2) and 28 studies with 1938 individuals described 
characteristics of patients with advanced fibrosis (AF) (supplementary table 3). Sixty-seven 
RCTs were included. These studies included a total of 4,846 individuals (supplementary 
table 4). 
 
The methods used to diagnose NAFLD varied. Most population-based studies used 
imaging techniques, predominantly ultrasound, to define NAFLD whilst the majority of 
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secondary-care based studies used histology. NASH and AF were usually defined using 
the system proposed by Kleiner and Brunt (15), although some earlier studies used 
descriptive terms. In these cases, bridging fibrosis and/or cirrhosis were regard as 
advanced fibrosis. Several studies did not report the variables of interest, or did so in such 
a manner that we were unable to extract data for use in the present study. Available data 
are summarised in supplementary table 5. 
 
Comparison of Randomised Controlled Trials and Observational Studies in NAFLD 
Analysis of unadjusted study-reported means from included studies showed significant 
variance in age, BMI, prevalence of diabetes and distribution of gender across all study 
cohorts (figure 2). To compare age and BMI between types of study weighted means 
were calculated to reflect the relative size of each study and compared with student’s t-
test, and absolute prevalence of diabetes and male gender compared with Chi-squared 
test (table 1). 
 
RCT and OS showed statistically significant differences with respect to age (mean age RCT 
50.0 years (SEM 0.09) vs. OS 49.4 years (SEM 0.06) student’s t-test p<0.001) and BMI (32.1 
kg/m2 (0.05) vs. 29.3 (0.03), p<0.001)(table 1, figure 3). Prevalence of diabetes and gender 
were compared by Chi-squared test (table 1). RCT and OS showed statistically significant 
differences with regard to the prevalence of diabetes (8%, 337 of 4186 participants, vs. 
24%, 5561 of 23162 individuals, p<0.001) and gender of participants (55% male, 2617 of 
4733 participants, vs. 50%, 12,405 of 24,648 individuals, p<0.001) (table 1, figure 4). 
 
Subgroup analyses were performed to compare individuals with NASH or advanced 
fibrosis in OS to RCT participants. Age did not differ between RCT and individuals with 
biopsy-proven NASH (mean age RCT 50.0 years (0.09) vs. 49.9 (0.18), p=0.520) but did 
differ between RCT and individuals with advanced fibrosis (mean age 54.0 years (0.19), 
p<0.001) (table 1, figure 3). BMI differed significantly between RCT participants and 
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individuals with NASH (mean BMI RCT 32.1 (0.04) vs. 32.4 kg/m2 (0.09) p=0.009), and also 
between RCT participants and individuals with advanced fibrosis (33.8 kg/m2 (0.08), 
p<0.001) (table 1, figure 3).  
 
The prevalence of DM and gender also differed significantly between RCT participants 
and individuals with NASH or advanced fibrosis. In RCTs, 8%, (337 participants) had DM. 
In observational studies, 39% of individuals with NASH (829 of 2145 participants) and 45% 
of individuals with advanced fibrosis (782 of 1726 participants) had DM (Chi squared test 
p<0.001 in each case)(table 1, figure 4). In RCTs, 55% of participants were male compared 
to 47% of individuals with NASH (1170 of 2476 individuals) and 38% of individuals with 
advanced fibrosis (712 of 1869 individuals) (Chi squared test p<0.001 in each case) (table 
1, figure 4).   
 
Analysis by geography 
Ethnicity is associated with marked phenotypic differences in NAFLD (16, 17). In view of 
this observational studies were stratified based on geographic location (supplementary 
figure 2). BMI and gender distribution showed significant differences by geographic 
location (Kruskal-Wallis test p<0.0001 and <0.01 respectively). Accordingly, BMI and 
gender distribution in observational studies and RCTs were compared by geographical 
location. Significant differences remained between observational studies and RCTs (t-test 
of weighted means p<0.001). Again, these differences were most pronounced between 
RCTs and individuals with advanced fibrosis, with the exception of European data 
(supplementary figure 3). When considering results for gender, European data showed no 
differences between populations. In Asia and North America, RCTs contained significantly 
more men than were observed in epidemiological studies of advanced fibrosis 
(supplementary figure 4). 
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Exclusion criteria of RCT in NAFLD  
The exclusion criteria of all identified RCT were reviewed. Eighteen trials including 2008 
participants (41% of all participants) excluded patients with cirrhosis. Participants with DM 
were excluded in 17 studies (1144 participants, 24% of total) and exclusion criteria based 
on medications to treat DM were reported in a further 22 studies (1643 participants, 34% 
of total). Thus, the presence of DM represented an absolute or relative exclusion criterion 
in 39 trials including 2,787 participants (58% of all RCT participants). Individuals using 
drugs to treat dyslipidaemia were excluded in 7 trials (375 participants, 8%).  
Discussion 
These data, derived from a robust systematic review, show that characteristics of 
individuals with NAFLD in observational studies differ from those included in RCT. These 
differences are statistically significant but are often small and may not be clinically 
significant. However, marked differences exist between RCT cohorts and individuals with 
advanced fibrosis who are more likely to progress to liver-related morbidity. This is 
compounded by the frequent exclusion of patients with cirrhosis or diabetes from trials. 
These differences may limit the application of RCT trial data to high-risk patients with 
NAFLD.  
 
There are important differences in susceptibility to insulin resitance and fatty liver btween 
indiviiduals of differing ethnicity (2, 16, 18). This was evident when studies were stratified 
by geography. Importantly, siginificant differences remained between OS and RCT 
populations.  
 
An explanation for the differences seen between OS and RCT may lie in the current 
paradigm that steatohepatitis is required for the development of liver fibrosis. Since this 
process takes many years to develop, RCTs in patients with NASH have often relied on 
histological criteria to recruit patients and assess efficacy. For instance the accepted 
endpoint of an <=2 point improvement in the NAFLD activity score (NAS) without 
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worsening of fibrosis (19), specifically excludes patients with cirrhosis since there is no way 
to evaluate whether fibrosis has worsened in this group.  Whilst RCT are necessarily 
different to real life clinical practice, use of this endpoint skews trial populations away from 
the groups at greatest risk of liver related morbidity and mortality, and towards younger 
patients with earlier disease.  This questions the value of current surrogate endpoints in 
NAFLD trials and raises important issues regarding the definition of such outcome 
measures in early phase studies for patients with NASH. In other liver diseases, such as 
hepatitis B virus infection, when liver disease is treated in patients with cirrhosis there is 
evidence of a reduction in fibrosis progression (20) and a concurrent reduction in the risk 
of liver related events. IT is important to discover whether this can also be achieved in 
patients with NASH and advanced fibrosis. 
 
An additional cause for the differences in observational cohorts and trial participants is the 
stringent exclusion criteria applied in RCT. In particular, diabetes per se or use of 
medications for diabetes is a frequent cause of exclusion of patients from trials, while 
nearly a quarter of patients (24%) have DM in observational studies of NAFLD and nearly 
half of patients (45%) with advanced fibrosis have DM. In some trials, for example trials of 
metformin or thiazolidinediones, limitations on diabetic patients or diabetic medications 
may be justified but the applicability of these findings to patients with advanced fibrosis is 
then limited.  The design of trials that exclude patients with both diabetes and cirrhosis is 
thus a major barrier to external validity since many of those patients at the greatest risk of 
liver related death are not represented in these studies. Recent notable trials in NAFLD 
have suggested that studies are bcoming more inclusive. For example, the recent trial of 
Elafibranor included around reported that over 30% of participants had diabetes (21).  
 
The American Association for the Study of Liver Disease (AASLD) published a consensus 
statement regarding trial design in NAFLD (22). This was added to in 2015 by a report of a 
meeting between representatives of the AASLD the US Food and Drug Administration 
(FDA) (19). These documents provide guidance that aims to achieve greater consistency in 
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trial design and to define outcomes relevant to patients. They do not provide 
recommendations on measures that might strengthen external validity per se but do 
recommend that trials in NAFLD should target specific groups, in particular those at risk of 
progression to cirrhosis, those with cirrhosis, and post-transplant patients. Advice from 
regulatory bodies regarding measures to improve of review external validity of trials is 
either lacking or non-binding.  
 
These findings are similar to studies in other disease areas.  In cardiovascular disease 
advanced patient age and the presence of co-morbidity were identified as important 
factors limiting external validity (9).  The issue of co-morbidity is also important in patients 
with NAFLD.  The association of NAFLD with the metabolic syndrome raises the risk of co-
existing cardiovascular disease, prior extra-hepatic cancer, and other obesity related 
complications (23) that may also impact on recruitment into clinical trials.  It is important 
that these co-morbidities are considered in future trial design.  It is likely that inclusion of 
patients with significant co-morbidities would increase the risk of competing mortality 
such that in large scale, long duration licensing studies the number of patients required 
for sufficient statistical power would also be increased. Thus there is a short-term 
disincentive to include such patients in registration studies. In the long-term however it is 
preferable that physicians and patients understand the likely benefits and harms of 
treatment and this can only be achieved through the inclusion of such patients in licensing 
studies of novel therapeutics for patients with NASH. 
 
This study has several limitations.  It is limited by missing data, which also reflects data 
being presented in a manner that was not suitable for analysis in this study. Nevertheless, 
the comprehensive systematic review and consequent large numbers studies included 
goes some way to limiting the impact of these missing data. There is also a risk of bias in 
the selection of patients for inclusion in observational studies of NASH and advanced 
fibrosis, through selection for biopsy, which may only be performed in patients who 
appear at high risk to clinicians. This is also the case in observational studies based in 
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secondary care where a degree of selection bias may be present. The larger community 
based studies using non-invasive methods to diagnose NAFLD are less at risk of these 
biases.  
 
In conclusion, we have identified differences in the characteristics of patients identified in 
observational studies of NASH, particularly those with advanced fibrosis, and those 
patients enrolled in RCTs of new therapeutic approaches.  These findings, whilst partially 
explained by the therapies that have been trialed and by the choice of surrogate 
endpoint, highlight a risk that future studies will have limited external validity. 
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Weighted means of age and BMI 
 
 
 
RCT cohorts 
Observational studies 
All NAFLD NASH Adv. fibrosis 
Mean SEM Mean 
SE
M 
Difference 
between 
means 
p 
t-test 
Mean SEM 
Difference 
between 
means 
p 
t-test 
Mean SEM 
Difference 
between 
means 
p 
t-test 
Age  
(years) 
50.0 0.09 49.4 
0.0
4 
-0.64 <0.0001 49.8 0.18 -0.16 0.424 54.0 0.19 3.96 <0.0001 
BMI  
(kg/m
2
) 
32.1 0.05 29.3 
0.0
1 
-2.83 <0.0001 32.3 0.09 0.20 0.043 33.8 0.08 1.67 <0.0001 
Calculated prevalence of diabetes, distribution of gender 
 
RCT cohorts 
Observational studies 
All NAFLD NASH Advanced fibrosis 
prevalence prevalence 
p 
Chi-squared 
prevalence 
p 
Chi-squared 
prevalence 
p 
Chi-squared 
Prevalence 
of Diabetes 
(%) 
8 24 <0.001 39 <0.001 46 <0.001 
Male 
gender 
(%) 
56 51 <0.001 48 <0.001 39 <0.001 
  
Table 1:  Characteristics of RCT and observational study cohorts. p-value refers to difference of observational studies to RCT cohort. 
 
This article is protected by copyright. All rights reserved. 
Figure Legends 
 
Figure 1. Flow chart of literature search outcomes. 
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Figure 2: Distribution of variables between types of study: A age, B BMI, where each point 
represents the mean value from an individual trial. C prevalence of diabetes and D male 
gender, each data point represents prevalence within an individual study. Lines at median 
and interquartile range. *p<0.05, **p<0.001, ***p<0.001 by Kruskal-Wallis test. 
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Figure 3:  Age and BMI of participants in observational studies and RCTs. Data are shown 
as weighted mean, horizontal lines represent standard deviation. Dashed line at RCT 
mean. ***p<0.001 by student’s t-test 
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Figure 4: Prevalence of diabetes and distribution of gender in observational studies and 
RCTs. ***p<0.001 by Chi-squared test 
 
 
